{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:41Z","timestamp":1786996781257,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:15:21Z","timestamp":1749755721000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel biomarkers for guiding treatment for prostate cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-218X","authenticated-orcid":false,"given":"David D.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2025.04.002_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0002","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0003","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(17)35410-1","article-title":"The use of prostate specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer","volume":"150","author":"Partin","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0004","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","article-title":"A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer","volume":"90","author":"Kattan","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0006","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0007","article-title":"Prostate cancer","volume":"1","year":"2025","journal-title":"Version"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0008","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ijrobp.2017.06.233","article-title":"Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk","volume":"99","author":"Spratt","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0013","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/1471-2164-14-690","article-title":"Analytical validation of the Oncotype DX prostate cancer assay\u2014A clinical RT-PCR assay optimized for prostate needle biopsies","volume":"14","author":"Knezevic","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0014","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","article-title":"A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease","volume":"73","author":"Van Den Eeden","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0016","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","article-title":"A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer","volume":"68","author":"Cullen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0017","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","volume":"106","author":"Cuzick","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0019","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.juro.2014.02.003","article-title":"Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy","volume":"192","author":"Bishoff","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0021","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijrobp.2013.04.043","article-title":"Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy","volume":"86","author":"Freedland","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0022","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0023","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bju.13911","article-title":"Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance","volume":"120","author":"Tosoian","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00364","article-title":"Validation of the combined clinical cell-cycle risk score to prognosticate early prostate cancer metastasis from biopsy specimens and comparison with other routinely used risk classifiers","author":"Hutten","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/JU.0000000000002922","article-title":"Cell cycle progression score, but not phosphatase and tensin homolog loss, is an independent prognostic factor for metastasis in intermediate- and high-risk prostate cancer in men treated with and without salvage radiotherapy","volume":"208","author":"Trock","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0026","first-page":"123","article-title":"Health economic impact and prospective clinical utility of Oncotype DX\u00ae Genomic prostate score","volume":"18","author":"Albala","year":"2016","journal-title":"Rev Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0027","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2217\/fon-2020-0648","article-title":"Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer","volume":"16","author":"Gustavsen","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0028","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamaoncol.2020.6086","article-title":"Regional adoption of commercial gene expression testing for prostate cancer","volume":"7","author":"Leapman","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0029","first-page":"15","article-title":"The present and future of biomarkers in prostate cancer: Proteomics, genomics, and immunology advancements","volume":"8","author":"Gaudreau","year":"2016","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0030","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"0","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0032","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0033","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/bjc.2014.396","article-title":"Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error","volume":"111","author":"Shipitsin","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0034","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-14-2603","article-title":"Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer","volume":"21","author":"Blume-Jensen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12894-017-0243-1","article-title":"Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists\u2019 recommendations for active treatment or active surveillance: a randomized clinical utility trial","volume":"17","author":"Peabody","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0036","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0037","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0038","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0039","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","article-title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: A matched, retrospective analysis","volume":"17","author":"Zhao","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.01.017","article-title":"Predicting dose-response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG\/RTOG 0126 and SAKK 09\/10 trials","author":"Dal Pra","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0041","article-title":"Harnessing artificial intelligence for prostate cancer management","volume":"5","author":"Zhu","year":"2024","journal-title":"CR Med"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0042","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41598-022-07217-0","article-title":"A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies","volume":"12","author":"Singhal","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0043","article-title":"Predicting prostate cancer grade reclassification on active surveillance using a deep learning-based grading algorithm","volume":"139","author":"Ding","year":"2024","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0044","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0046","article-title":"Prostate cancer risk stratification in NRG oncology phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0047","doi-asserted-by":"crossref","first-page":"S979","DOI":"10.1016\/j.annonc.2024.08.1702","article-title":"1621P Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy","volume":"35","author":"Bjartell","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5001","article-title":"Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG\/RTOG trials","volume":"41","author":"Armstrong","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0049","doi-asserted-by":"crossref","unstructured":"Wu, J, Duan, B, Kang, W, et al. Token transformation matters: towards faithful post-hoc explanation for vision transformer. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2403.14552 (2024).","DOI":"10.1109\/CVPR52733.2024.01039"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2020.103655","article-title":"The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies","volume":"113","author":"Markus","year":"2021","journal-title":"J Biomed Informat"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114292","article-title":"Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study","volume":"211","author":"Dernbach","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0052","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41591-024-02857-3","article-title":"Towards a general-purpose foundation model for computational pathology","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0053","unstructured":"Zimmermann, E et al. Virchow2: Scaling self-supervised mixed magnification models in pathology. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2408.00738 (2024)."},{"key":"10.1016\/j.semradonc.2025.04.002_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2022.102559","article-title":"Transformer-based unsupervised contrastive learning for histopathological image classification","volume":"81","author":"Wang","year":"2022","journal-title":"Med Image Anal"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41586-024-07441-w","article-title":"A whole-slide foundation model for digital pathology from real-world data","volume":"630","author":"Xu","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0056","unstructured":"Ding, T et al. Multimodal whole Slide Foundation model for pathology. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2411.19666 (2024)."},{"key":"10.1016\/j.semradonc.2025.04.002_bib0057","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0058","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0059","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/JU.0000000000001821","article-title":"The prognostic association of prostate MRI PI-RADSTM v2 assessment category and risk of biochemical recurrence after definitive local therapy for prostate cancer: A systematic review and meta-analysis","volume":"206","author":"Rajwa","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.euo.2022.09.005","article-title":"Magnetic resonance imaging-based T-staging to predict biochemical recurrence after radical prostatectomy: A step towards the iTNM classification","volume":"6","author":"Baboudjian","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0061","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2021.07.027","article-title":"Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: Development and external validation of novel Risk groups","volume":"81","author":"Mazzone","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0062","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/j.clgc.2022.06.010","article-title":"The clinical significance of maximum tumor diameter on MRI in men undergoing radical prostatectomy or definitive radiotherapy for locoregional prostate cancer","volume":"20","author":"Hutten","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0063","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.240041","article-title":"AI-derived tumor volume from multiparametric MRI and outcomes in localized prostate cancer","volume":"313","author":"Yang","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0064","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging\u2014\u201chow-to\u201d guide and critical reflection","volume":"11","author":"van Timmeren","year":"2020","journal-title":"Insights Into Imaging"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm.3984","article-title":"Pan-cancer analysis of the extent and consequences of intra-tumor heterogeneity","volume":"22","author":"Andor","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0066","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1166047","article-title":"Delta radiomic patterns on serial bi-parametric MRI are associated with pathologic upgrading in prostate cancer patients on active surveillance: preliminary findings","volume":"13","author":"Midya","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103163","article-title":"A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI","volume":"63","author":"Li","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0069","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222223","article-title":"An MRI deep learning model predicts outcome in rectal cancer","volume":"307","author":"Jiang","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7516035","article-title":"eHealth Cloud security challenges: A survey","volume":"2019","author":"Al-Issa","year":"2019","journal-title":"J Healthc Eng"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0071","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41467-024-44946-4","article-title":"Robustly federated learning model for identifying high-risk patients with postoperative gastric cancer recurrence","volume":"15","author":"Feng","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0072","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jmri.27623","article-title":"Voxel-level classification of prostate cancer on MRI: Improving accuracy using four-compartment restriction spectrum imaging","volume":"54","author":"Feng","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0073","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1148\/radiol.2016152542","article-title":"Interobserver reproducibility of the PI-RADS version 2 lexicon: A multicenter study of six experienced prostate radiologists","volume":"280","author":"Rosenkrantz","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0074","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.radonc.2015.04.012","article-title":"Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation","volume":"115","author":"Steenbergen","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0075","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2023.07.004","article-title":"ReIGNITE RT Boost: a prospective, international study of radiation oncologists\u2019 accuracy in contouring prostate tumors for focal radiotherapy boost on conventional MRI alone or with assistance of restriction spectrum imaging (RSI)","volume":"117","author":"Lui","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0076","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2214\/AJR.17.18849","article-title":"Diagnostic utility of a likert scale versus qualitative descriptors and length of capsular contact for determining extraprostatic tumor extension at multiparametric prostate MRI","volume":"210","author":"Costa","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0077","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/radiol.2018181278","article-title":"A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI","volume":"290","author":"Mehralivand","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0078","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020192133","article-title":"Extraprostatic tumor extension: Comparison of preoperative multiparametric MRI criteria and histopathologic correlation after radical prostatectomy","volume":"296","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0079","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1016\/j.acra.2024.04.011","article-title":"Automated detection and grading of extraprostatic extension of prostate cancer at MRI via cascaded deep learning and random forest classification","volume":"31","author":"Simon","year":"2024","journal-title":"Acad Radiol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0080","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/annonc\/mdx034","article-title":"Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology","volume":"28","author":"Limkin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0081","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0082","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0083","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0084","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.ijrobp.2024.07.242","article-title":"A validation study on the impact of decipher\u00ae testing on treatment recommendations in African American and Non-African American men with prostate cancer (VANDAAM STUDY)","volume":"120","author":"Yamoah","year":"2024","journal-title":"Int J Radiat Oncol Biol, Phys"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0085","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41391-019-0197-3","article-title":"Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting","volume":"23","author":"Howard","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0086","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1078-0432.CCR-21-2577","article-title":"Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors","volume":"28","author":"Stopsack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0087","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2025.04.002_bib0088","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ccell.2022.09.012","article-title":"Artificial intelligence for multimodal data integration in oncology","volume":"40","author":"Lipkova","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962500030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342962500030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:05:43Z","timestamp":1750777543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105342962500030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S105342962500030X"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.002","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel biomarkers for guiding treatment for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}